傳奇生物和Noile-Immune宣布合作協議

- 共同開發針對實體腫瘤的下一代細胞療法

薩默塞特，新澤西，美國； 東京，日本；5月4日

致力于開發創新細胞療法的臨床階段的生物制藥公司傳奇生物今天欣然宣布與Noile-Immune 生物技術公司（Noile）的合作。雙方達成達成了關于Noile公司的 PRIME 技術的授權和合作協議。PRIME技術運用細胞分泌白細胞介素7（Interlukin-7, IL7）和趨化因子配體19 （Chemokine C-C motif ligand 19, IL-19），從而增強T淋巴細胞的增殖和在體內的遷徙能力。根據此協議，傳奇生物將使用Noile的PRIME技術來增強CAR-T和TCR-T，以及病人T細胞的擴增和向腫瘤趨化的能力。

“我們很高興與Noile建立戰略合作關系，把我們在細胞治療領域的研發和Noile的PRIME技術相結合。”傳奇生物的首席科學官范曉虎博士評論道，“我們致力于將傳奇的針對實體瘤的細胞療法和Noile的創新技術相結合，力爭為癌癥病人開發新型的高度有效的療法。”

“細胞治療正往實體瘤領域拓展，關于增強CAR-T往腫瘤部位遷徙的能力對于產品開發非常重要。”傳奇生物董事會董事，首席執行官許遠博士評論道，“這次合作顯示了傳奇生物致力于為實體腫瘤開發創新療法的決心。”

“與傳奇生物達成戰略合作是一項重要成就。傳奇生物已經將細胞療法帶入臨床開發階段，并顯示了細胞治療的希望和前景。”Nolie的董事，科學創始人 Koji Tamada博士說到，“從科學的角度，將PRIME技術和傳奇生物的創新項目相結合，我們的目標是對多種實體瘤開發高效的療法，進一步拓展腫瘤免疫治療的應用。”

“這次與傳奇生物達成的合作再次顯示了業界對PRIME技術的熱情”，Noile首席執行官Hidenobu Ishizaki 評論道，“這次合作將加快創新細胞免疫治療的開發。我們十分期待和傳奇生物的合作，共同把癌癥治療的革新技術帶給病患。”

在這項合作中，傳奇生物和Noile 將共同開發不多于2個癌癥靶點項目。傳奇將獲得PRIME技術在CAR-T和TCR-T開發中的使用權。 對每個合作的項目，傳奇將支付總計可達七千萬美金的費用，涵蓋開發，申報和商業化等里程碑。Noile 也享有商品化以后個位數百分比的銷售分成的權益。

關于傳奇生物

傳奇生物是一家在臨床階段的全球生物制藥公司，致力于針對癌癥和其它適應癥的創新細胞療法的開發。傳奇生物公司已在美國，歐洲，和中國均有運營。更多訊息請訪問https://www.legendbiotech.com/。

關于Noile-Immune 生物技術公司

位于日本東京的Noile-Immune 生物技術公司致力于運用創新技術開發和商品化腫瘤免疫療法。公司通過與包括山口大學和日本國家癌癥中心的合作，開發新穎的腫瘤免疫療法，為病患提供一流的治療方案。更多信息，請訪問https://www.noileimmune.com/english/home/。

關于前瞻性陳述的注意事項

This information constitutes forward-looking statements relating to the business of Legend, including express or implied discussions regarding the anticipated benefits from the collaboration agreement with Noile-Immune and its PRIME technology and the ability to develop potential new therapies to address cancer in solid tumors, the clinical development of its product candidates and potential attributes and benefits of such product candidates. Such forwardlooking statements reflect the current views of Legend’s management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, Legend’s expectations could be affected by, among other things, uncertainties involved in the ability to implement PRIME technology into Legend’s product candidate pipeline, the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulationgenerally; Legend’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

The safety and efficacy of the product candidates and/or uses under investigation have not been established. There is no guarantee that the product candidates will receive health authority approval or become commercially available in any country for the uses being investigated.

The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.

傳奇生物媒體和投資人聯絡

媒體聯絡
Deborah Wong, Executive Director, Strategic Marketing & Corporate Communication, Legend Biotech
deborah.wong@legendbiotech.com or media@legendbiotech.com

投資者關系
Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com

Noile-Immune 聯系方式

Tsutom Tokashiki, Executive Director, Senior Vice President, Business Development, Noile-Immune Biotech
ir@noile-immune.com